BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sarilumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sarilumab\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05535738-5897@assetmemo.bio
DTSTAMP:20261121T005844Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Sarilumab: Phase 2/3 readout est. (NCT05535738)
DESCRIPTION:Sarilumab\, phase 2/3.\nStudy: Using a Contact Dermatitis Model
  With Biologic Medications to Study Skin Inflammation\nEstimated primary c
 ompletion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/sarilumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05535738
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05704634-5897@assetmemo.bio
DTSTAMP:20261121T005844Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Sarilumab: Phase 1 readout est. (NCT05704634)
DESCRIPTION:Sarilumab\, phase 1.\nStudy: A Phase Ib Study to Evaluate the S
 afety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combi
 nation With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell L
 ung Cancer.\nEstimated primary completion: 1 January 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sarilumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05704634
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-5897@assetmemo.bio
DTSTAMP:20261121T005844Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Sarilumab: Phase 3 readout est. (NCT03414502)
DESCRIPTION:Sarilumab\, phase 3\, Rheumatoid Arthritis.\nStudy: Treatment o
 f Rheumatoid Arthritis With DMARDs: Predictors of Response\nEstimated prim
 ary completion: March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/sarilumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT03414502
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02991469-5897@assetmemo.bio
DTSTAMP:20261121T005844Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Sarilumab: Phase 2 readout est. (NCT02991469)
DESCRIPTION:Sarilumab\, phase 2\, Systemic Juvenile Idiopathic Arthritis.\n
 Study: A Repeated Dose-finding Study of Sarilumab in Children and Adolesce
 nts With Systemic Juvenile Idiopathic Arthritis (SKYPS)\nEstimated primary
  completion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/sarilumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT02991469
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05428007-5897@assetmemo.bio
DTSTAMP:20261121T005844Z
DTSTART;VALUE=DATE:20280317
DTEND;VALUE=DATE:20280318
SUMMARY:Sarilumab: Phase 2 readout est. (NCT05428007)
DESCRIPTION:Sarilumab\, phase 2.\nStudy: Interleukin-6 Receptor Inhibitor S
 arilumab in Combination With Ipilimumab\, Nivolumab and Relatlimab in Pati
 ents With Unresectable Stage III or Stage IV Melanoma\nEstimated primary c
 ompletion: 17 March 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/sarilumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05428007
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07484113-5897@assetmemo.bio
DTSTAMP:20261121T005844Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Sarilumab: Phase 1 readout est. (NCT07484113)
DESCRIPTION:Sarilumab\, phase 1.\nStudy: IL6-receptor Inhibitor Iwith Belum
 osudil for the Treatment of Belumosudil-refractory cGVHD\nEstimated primar
 y completion: May 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sarilumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07484113
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02735707-5897@assetmemo.bio
DTSTAMP:20261121T005844Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sarilumab: Phase 3 readout est. (NCT02735707)
DESCRIPTION:Sarilumab\, phase 3.\nStudy: Randomized\, Embedded\, Multifacto
 rial Adaptive Platform Trial for Community- Acquired Pneumonia\nEstimated 
 primary completion: June 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/sarilumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT02735707
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07704580-5897@assetmemo.bio
DTSTAMP:20261121T005844Z
DTSTART;VALUE=DATE:20281026
DTEND;VALUE=DATE:20281027
SUMMARY:Sarilumab: Phase 1/2 readout est. (NCT07704580)
DESCRIPTION:Sarilumab\, phase 1/2\, Rheumatoid Arthritis.\nStudy: Phase 1b/
 2 Study of IV Sarilumab in Adult With RA\nEstimated primary completion: 26
  October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sarilu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07704580
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286214-5897@assetmemo.bio
DTSTAMP:20261121T005844Z
DTSTART;VALUE=DATE:20290604
DTEND;VALUE=DATE:20290605
SUMMARY:Sarilumab: Phase 3 readout est. (NCT07286214)
DESCRIPTION:Sarilumab\, phase 3.\nStudy: Sarilumab Efficacy and Safety in A
 dults With Early Polymyalgia Rheumatica\nEstimated primary completion: 4 J
 une 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sarilumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07286
 214
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836101-5897@assetmemo.bio
DTSTAMP:20261121T005844Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Sarilumab: Phase 2 readout est. (NCT07836101)
DESCRIPTION:Sarilumab\, phase 2.\nStudy: Study of Sarilumab With Immune Che
 ckpoint Inhibitor Rechallenge in Patients With Clinically Significant Immu
 ne Related Adverse Events\nEstimated primary completion: August 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sarilumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07836101
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-5897@assetmemo.bio
DTSTAMP:20261121T005844Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Sarilumab: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Sarilumab\, phase 2.\nStudy: I-SPY TRIAL: Neoadjuvant and Perso
 nalized Adaptive Novel Agents to Treat Breast Cancer\nEstimated primary co
 mpletion: December 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sarilumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT01042379
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
